News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RepRegen™ Ltd. (Formerly Known as BioCeramic Therapeutics) Discloses Six-Month in Vivo Data Confirming Bone-Regeneration Properties of Stronbone(TM) Bone Graft Substitute - the First Product from the Company's Platform to Repair and Regenerate Hard Tissue, Such as Bone



9/30/2010 9:41:48 AM

LONDON--(BUSINESS WIRE)--RepRegen™, the ‘smart biomaterials’ company, announced today that three- and six-month data from an in vivo study of its CE-marked StronBone™ Bone Graft Substitute with Strontium demonstrated by analytical testing that it can generate bone quality in, and around, bone defects that is significantly superior to a standard bone void filler (TCP-CaSO4) in the control defect.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES